We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A greyscale headshot of Michele Trott

Michele Trott, PhD profile page

Scientific Content Manager

 at Izon Science


Michele Trott (nee Wilson) is a New Zealand-based science writer who pursues freelance writing projects alongside her in-house role as a scientific content writer at Izon Science. After completing her PhD (Endocrinology) at Lincoln University (NZ), Michele began pursuing her science writing career with Technology Networks in the UK. There, she spent 12 months covering a maternity leave role as a science editor, and managed the cell science, biopharma and diagnostics communities. Upon her arrival back in NZ, Michele established “Choice Science Writing” and became a full-time freelance science writer, working with life science marketing agencies, biotech companies – and of course, Technology Networks – to produce engaging articles and blog posts. In April 2021, she took up the opportunity to join the team at Izon Science, a company that enables the precise separation and analysis of extracellular vesicles and other nanoparticles.


Got a Question for Michele Trott, PhD?


Get in touch using the contact form linked here and we’ll get back to you shortly.



Published Content
Total: 111
The Hunt for Therapeutic Antibodies content piece image
Article

The Hunt for Therapeutic Antibodies

Given the clinical success that antibodies (formerly known as “magic bullets”) have facilitated, the drug discovery field continues to search for new therapeutic candidates. This article highlights several techniques used in the process, and touches on current trends driving the field.
Industry Insight

The Vision for Multi-organ Human-on-a-Chip Models

The development of organ-on-a-chip models aims to reduce the (expensive) high drug failure rates that exist in clinical trials. A Florida biotech firm recently reported that their multi-organ “human-on-a-chip” system maintains cellular viability over 28 days in serum-free conditions, using a pumpless system. To learn more about the vision for multi-organ “human-on-a-chip” models, we caught up with James Hickman, Chief Science Officer of Hesperos Inc.
News

Japan Approves Stem Cell Therapy for Spinal Cord Injuries

A stem cell therapy has been given the green light for the treatment of spinal cord injuries, and a follow-up trial is set to begin later this year. However, independent researchers warn that the approval is premature.
Industry Insight

Is Off-the-Shelf Immunotherapy the Way Forward?

An “off-the-shelf” immuno-oncology product has been developed whereby T cells are derived from healthy donors, bypassing limitations related to high pricing and limited market access.
Exosomes: Tiny Vesicles With Enormous Potential  content piece image
Infographic

Exosomes: Tiny Vesicles With Enormous Potential

There's more to exosomes than first thought. This infographic provides a snapshot of the tiny cell-derived vesicles which have captured the attention of cell biologists and the medical world.
Industry Insight

Is Off-the-Shelf Immunotherapy the Way Forward?

An “off-the-shelf” immuno-oncology product has been developed whereby T cells are derived from healthy donors, bypassing limitations related to high pricing and limited market access.
Industry Insight

Biosimilar Surge Driving Need for Antibody Characterization

Accurate protein characterization is particularly important in the biopharmaceutical industry, where product modifications can affect efficacy and safety. Here, we speak to Matthew Lauber, a consulting scientist who elaborates on the importance and challenges of biotherapeutic protein characterization, and discusses different techniques used for charge variant analysis.
Industry Insight

Biosimilar Surge Driving Need for Antibody Characterization

Accurate protein characterization is particularly important in the biopharmaceutical industry, where product modifications can affect efficacy and safety. Here, we speak to Matthew Lauber, a consulting scientist who elaborates on the importance and challenges of biotherapeutic protein characterization, and discusses different techniques used for charge variant analysis.
Industry Insight

Antibody Cascade Design Key to Customizing Success

We caught up with Abcam's Head of Custom Services, Jamie Campbell, who recently presented at the Protein & Antibody Engineering Summit, Europe. Jamie discusses the company’s approach to discovering antibodies – key reagents in drug discovery, in vitro diagnostics and therapeutics.
Industry Insight

Antibody Cascade Design Key to Customizing Success

We caught up with Abcam's Head of Custom Services, Jamie Campbell, who recently presented at the Protein & Antibody Engineering Summit, Europe. Jamie discusses the company’s approach to discovering antibodies – key reagents in drug discovery, in vitro diagnostics and therapeutics.
Advertisement